Cargando…
Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata
Rhizomelic chondrodysplasia punctata (RCDP) is a rare genetic disorder caused by mutations in peroxisomal genes essential for plasmalogen biosynthesis. Plasmalogens are a class of membrane glycerophospholipids containing a vinyl-ether-linked fatty alcohol at the sn-1 position that affect functions i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994958/ https://www.ncbi.nlm.nih.gov/pubmed/31862688 http://dx.doi.org/10.1242/dmm.042499 |
_version_ | 1783493292626804736 |
---|---|
author | Fallatah, Wedad Smith, Tara Cui, Wei Jayasinghe, Dushmanthi Di Pietro, Erminia Ritchie, Shawn A. Braverman, Nancy |
author_facet | Fallatah, Wedad Smith, Tara Cui, Wei Jayasinghe, Dushmanthi Di Pietro, Erminia Ritchie, Shawn A. Braverman, Nancy |
author_sort | Fallatah, Wedad |
collection | PubMed |
description | Rhizomelic chondrodysplasia punctata (RCDP) is a rare genetic disorder caused by mutations in peroxisomal genes essential for plasmalogen biosynthesis. Plasmalogens are a class of membrane glycerophospholipids containing a vinyl-ether-linked fatty alcohol at the sn-1 position that affect functions including vesicular transport, membrane protein function and free radical scavenging. A logical rationale for the treatment of RCDP is therefore the therapeutic augmentation of plasmalogens. The objective of this work was to provide a preliminary characterization of a novel vinyl-ether synthetic plasmalogen, PPI-1040, in support of its potential utility as an oral therapeutic option for RCDP. First, wild-type mice were treated with (13)C(6)-labeled PPI-1040, which showed that the sn-1 vinyl-ether and the sn-3 phosphoethanolamine groups remained intact during digestion and absorption. Next, a 4-week treatment of adult plasmalogen-deficient Pex7(hypo/null) mice with PPI-1040 showed normalization of plasmalogen levels in plasma, and variable increases in plasmalogen levels in erythrocytes and peripheral tissues (liver, small intestine, skeletal muscle and heart). Augmentation was not observed in brain, lung and kidney. Functionally, PPI-1040 treatment normalized the hyperactive behavior observed in the Pex7(hypo/null) mice as determined by open field test, with a significant inverse correlation between activity and plasma plasmalogen levels. Parallel treatment with an equal amount of ether plasmalogen precursor, PPI-1011, did not effectively augment plasmalogen levels or reduce hyperactivity. Our findings show, for the first time, that a synthetic vinyl-ether plasmalogen is orally bioavailable and can improve plasmalogen levels in an RCDP mouse model. Further exploration of its clinical utility is warranted. This article has an associated First Person interview with the joint first authors of the paper. |
format | Online Article Text |
id | pubmed-6994958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-69949582020-02-03 Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata Fallatah, Wedad Smith, Tara Cui, Wei Jayasinghe, Dushmanthi Di Pietro, Erminia Ritchie, Shawn A. Braverman, Nancy Dis Model Mech Research Article Rhizomelic chondrodysplasia punctata (RCDP) is a rare genetic disorder caused by mutations in peroxisomal genes essential for plasmalogen biosynthesis. Plasmalogens are a class of membrane glycerophospholipids containing a vinyl-ether-linked fatty alcohol at the sn-1 position that affect functions including vesicular transport, membrane protein function and free radical scavenging. A logical rationale for the treatment of RCDP is therefore the therapeutic augmentation of plasmalogens. The objective of this work was to provide a preliminary characterization of a novel vinyl-ether synthetic plasmalogen, PPI-1040, in support of its potential utility as an oral therapeutic option for RCDP. First, wild-type mice were treated with (13)C(6)-labeled PPI-1040, which showed that the sn-1 vinyl-ether and the sn-3 phosphoethanolamine groups remained intact during digestion and absorption. Next, a 4-week treatment of adult plasmalogen-deficient Pex7(hypo/null) mice with PPI-1040 showed normalization of plasmalogen levels in plasma, and variable increases in plasmalogen levels in erythrocytes and peripheral tissues (liver, small intestine, skeletal muscle and heart). Augmentation was not observed in brain, lung and kidney. Functionally, PPI-1040 treatment normalized the hyperactive behavior observed in the Pex7(hypo/null) mice as determined by open field test, with a significant inverse correlation between activity and plasma plasmalogen levels. Parallel treatment with an equal amount of ether plasmalogen precursor, PPI-1011, did not effectively augment plasmalogen levels or reduce hyperactivity. Our findings show, for the first time, that a synthetic vinyl-ether plasmalogen is orally bioavailable and can improve plasmalogen levels in an RCDP mouse model. Further exploration of its clinical utility is warranted. This article has an associated First Person interview with the joint first authors of the paper. The Company of Biologists Ltd 2020-01-24 /pmc/articles/PMC6994958/ /pubmed/31862688 http://dx.doi.org/10.1242/dmm.042499 Text en © 2020. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/4.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Research Article Fallatah, Wedad Smith, Tara Cui, Wei Jayasinghe, Dushmanthi Di Pietro, Erminia Ritchie, Shawn A. Braverman, Nancy Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata |
title | Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata |
title_full | Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata |
title_fullStr | Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata |
title_full_unstemmed | Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata |
title_short | Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata |
title_sort | oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994958/ https://www.ncbi.nlm.nih.gov/pubmed/31862688 http://dx.doi.org/10.1242/dmm.042499 |
work_keys_str_mv | AT fallatahwedad oraladministrationofasyntheticvinyletherplasmalogennormalizesopenfieldactivityinamousemodelofrhizomelicchondrodysplasiapunctata AT smithtara oraladministrationofasyntheticvinyletherplasmalogennormalizesopenfieldactivityinamousemodelofrhizomelicchondrodysplasiapunctata AT cuiwei oraladministrationofasyntheticvinyletherplasmalogennormalizesopenfieldactivityinamousemodelofrhizomelicchondrodysplasiapunctata AT jayasinghedushmanthi oraladministrationofasyntheticvinyletherplasmalogennormalizesopenfieldactivityinamousemodelofrhizomelicchondrodysplasiapunctata AT dipietroerminia oraladministrationofasyntheticvinyletherplasmalogennormalizesopenfieldactivityinamousemodelofrhizomelicchondrodysplasiapunctata AT ritchieshawna oraladministrationofasyntheticvinyletherplasmalogennormalizesopenfieldactivityinamousemodelofrhizomelicchondrodysplasiapunctata AT bravermannancy oraladministrationofasyntheticvinyletherplasmalogennormalizesopenfieldactivityinamousemodelofrhizomelicchondrodysplasiapunctata |